Fundz

Medtech Company Stentit Raises €1.8 Million In Seed Round

PRIVATEApr 25, 2022

Amount Raised

€1.8 Million

Round Type

Seed

EindhovenConsumer GoodsHealth Care

Description

STENTiT, a medical device company bringing a novel class of regenerative endovascular implants for the treatment of cardiovascular diseases, has closed a €1.8 million seed investment round. The funding facilitates further pre-clinical development and batch production of a regenerative stent (see video) for peripheral indications. The investment was made by Dutch investors NextGen Ventures, Brabant Development Agency (BOM) and the Ten Cate Investment Company.

Who else raised in Consumer Goods and Health Care around the same time

Companies in the same sectors as Sten Ti T that raised within 45 days of this round, from Fundz verified event records.

  • Toothsi raised $40M (Funding Round) on May 2, 2022.
  • Upty raised an undisclosed amount (Seed) on April 25, 2022.
  • Open Book Extracts raised an undisclosed amount (Series C) on April 6, 2022.
  • Open Book Extracts raised $4.2M on April 5, 2022.
  • The Valens Company raised an undisclosed amount (Funding Round) on April 5, 2022.
  • Legion Health raised $3.7M (Seed) on March 17, 2022.

Who to call at Sten Ti T, and when

A new round usually means Sten Ti T is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Sten Ti T raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Sten Ti T, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Sten Ti T. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Sten Ti T

Location

Eindhoven, North Brabant, Netherlands

About

STENTiT is a medical device spin-off company from the Dutch Eindhoven University of Technology, focusing on the development of regenerative endovascular implants. These bioresorbable devices trigger a natural healing response by the circulating blood cells, in which the implant is being replaced by new vascular tissue to restore the artery from the inside-out. Since the establishment of the company, STENTiT has received broad international recognition and awards for its high-potential approach, covering world leading stages. As the company is currently going through the next translational phases, STENTiT is on its way to fulfill its ambition to become the new standard in endovascular treatment, providing a life-changing solution for millions of cardiovascular patients around the world. More information is available at www.stentit.com

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Sten Ti T raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Sten Ti T's next move

See what Strategic adds

Sten Ti T raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.